Erschienen in:
16.04.2021 | Brief Report
Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial
verfasst von:
Dolors Rodríguez-Pardo, María Dolores del Toro, Laura Guío-Carrión, Rosa Escudero-Sánchez, Marta Fernández-Sampedro, Miguel Ángel García-Viejo, María Velasco-Arribas, Laura Soldevila-Boixader, Magdalena Femenias, José Antonio Iribarren, María del Carmen Pulido-Garcia, María Dolores Navarro, Mayli Lung, Pablo S. Corona, Benito Almirante, Carles Pigrau
Erschienen in:
European Journal of Clinical Microbiology & Infectious Diseases
|
Ausgabe 11/2021
Einloggen, um Zugang zu erhalten
Abstract
Purpose
To evaluate preoperative asymptomatic bacteriuria (ASB) treatment to reduce early-periprosthetic joint infections (early-PJIs) after hip hemiarthroplasty (HHA) for fracture.
Methods
Open-label, multicenter RCT comparing fosfomycin-trometamol versus no intervention with a parallel follow-up cohort without ASB. Primary outcome: early-PJI after HHA.
Results
Five hundred ninety-four patients enrolled (mean age 84.3); 152(25%) with ASB (77 treated with fosfomycin-trometamol/75 controls) and 442(75%) without. Despite the study closed without the intended sample size, ASB was not predictive of early-PJI (OR: 1.06 [95%CI: 0.33–3.38]), and its treatment did not modify early-PJI incidence (OR: 1.03 [95%CI: 0.15–7.10]).
Conclusions
Neither preoperative ASB nor its treatment appears to be risk factors of early-PJI after HHA.
ClinicalTrials.gov Identifier: Eudra CT 2016-001108-47